Home > Insider Trading > Filing (0001385508-21-000119)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1385508	Opiant Pharmaceuticals Inc.	OPNT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1551246	Michael Sinclair	C/O Opiant Pharmaceuticals, Inc. 233 Wilshire Blvd, Suite 280 Santa Monica CA 90401		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, Par Value $0.001 Per Share	Acquisiton	2021-08-23	65,124	$5.00	209,194	No	4	M	Direct
Common Stock, Par Value $0.001 Per Share	Disposition	2021-08-23	65,124	$16.50	144,070	No	4	S	Direct
Common Stock, Par Value $0.001 Per Share	Acquisiton	2021-08-24	34,607	$5.00	178,677	No	4	M	Direct
Common Stock, Par Value $0.001 Per Share	Disposition	2021-08-24	34,607	$15.71	144,070	No	4	S	Direct
Common Stock, Par Value $0.001 Per Share	Acquisiton	2021-08-25	50,269	$5.00	194,339	No	4	M	Direct
Common Stock, Par Value $0.001 Per Share	Disposition	2021-08-25	50,269	$14.69	144,070	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, Par Value $0.001 Per Share	Options	Disposition	2021-08-23	65,124	$0.00	65,124	$5.00
Common Stock, Par Value $0.001 Per Share	Options	Disposition	2021-08-24	34,607	$0.00	34,607	$5.00
Common Stock, Par Value $0.001 Per Share	Options	Disposition	2021-08-25	50,269	$0.00	50,269	$5.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
84,876	2014-06-15	2024-06-14	No	4	M	Direct
50,269	2014-06-15	2024-06-14	No	4	M	Direct
0	2014-06-15	2024-06-14	No	4	M	Direct

Footnotes

This transaction was executed in multiple trades at prices ranging from $16.00 to $17.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $15.50 to $16.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $13.80 to $15.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
These options became exercisable on December 15, 2014 when Opiant Pharmaceuticals entered into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment with Adapt Pharma Operations Limited.